Compare Sea Limited (SE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sea Limited vs TG Therapeutics Inc — how do they compare? Sea Limited trades at $95.25 (market cap $56.89B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Sea Limited is far larger — about 7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sea Limited for 102 Days and TG Therapeutics Inc for 16 Days on average.
| SE | TGTX | |
|---|---|---|
Market Cap | $56.89B | $8.16B |
Volume | 5,359,457 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $182.60 | $59.06 |
52-Week Low | $78.16 | $26.94 |
Typical Hold Time | 102 Days | 16 Days |
Enterprise Value | $51.92B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $92.89, down 1.87% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. Fundamentally, the company demonstrates strong revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income improving to $1.58B. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a $153.67 consensus price target, representing 65% upside potential. Recent news highlights insider selling activity but also bullish analyst commentary on Shopee's growth prospects.
The investment case hinges on Sea's ability to maintain e-commerce momentum while improving profitability. Key risks include competitive pressures in Southeast Asian markets and execution challenges in scaling operations. With shares trading well below analyst targets and showing improved cash flow generation, the current price level presents a potential entry point for growth-oriented investors willing to tolerate near-term volatility.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
